Navigation Links
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
Date:12/29/2008

dicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic tools, which is unproven and may never lead to commercially accepted products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop and commercialize its candidate tools, products and services; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact: Media & Investors, Ron Kamienchick, T: +1-(646)-509-1893, E:

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
2. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
3. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
4. /C O R R E C T I O N -- Rosetta Genomics Ltd/
5. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
6. Rosetta Genomics to Present at Oppenheimers 19th Annual Healthcare Conference
7. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
8. Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
9. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
10. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Avure Technologies celebrates a year ... newest member of its fleet of high volume High Pressure ... anniversary as we return to PackExpo this year, which is ... Las Vegas,” said Jeff Williams, CEO at Avure. “Sales of ... pleased to be meeting the challenges of market demand for ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 /PRNewswire/ ... GNBT) today announced two presentations demonstrating that the ... novel proprietary cancer immunotherapeutic AE37 vaccine correlated with ... The AE37 cancer vaccine is being developed by ... www.antigenexpress.com ). The presentations are being made at ...
(Date:10/27/2014)... The report “Smart Highway Market by Technology ... and by Display (Variable Message Signs, Digital Signage) ... market into various sub-segments with in-depth analysis and ... and restraints for this market with insights into ... tables and 37 figures spread through 141 pages ...
Breaking Biology Technology:In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4
... , , WILMINGTON, Del., ... dispersible tablet (ODT) technologies with its patented Pharmaburst(R) and Pharmafreeze(TM) ... proprietary technology with superior organoleptics, Pharmaburst(R) 500 will most certainly ... formulators have come to expect from a quick-dissolve dosage form. ...
... WALTHAM, Mass., Aug. 11 Decision Resources, one of ... issues, finds that the entry and uptake of premium-priced biologics will ... from approximately $420 million in 2008 to nearly $2 billion in ... Systemic Lupus Erythematosus finds that the primary drivers of ...
... COLUMBIA, Md., Aug. 11 BP and Martek Biosciences ... a Joint Development Agreement (JDA) to work on the production of ... platform and operational capabilities to advance the development of a step-change ... , Under the terms of the multi-year agreement, Martek ...
Cached Biology Technology:Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 3BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 4
(Date:10/28/2014)... National University of Singapore (NUS) have discovered a new ... laying direct developing eggs in live bamboo with narrow ... bush frog ( Raorchestes chalazodes ). This critically ... known to adopt this novel reproductive strategy. The findings ... Biological Journal of the Linnean Society , in October ...
(Date:10/28/2014)... University Singapore (NTU Singapore) will be building a ... energy sources. , The first in the region, ... integration of solar, wind, tidal-current, diesel, storage and ... well together. , To be built under the ... the hybrid micro-grid will be located offshore at ...
(Date:10/27/2014)... a scientific one-two punch with a pair of papers ... sticky ends. , Collagen is the most common protein ... fibrous tissues that support cells and hold organs together. ... for tissue engineering and cosmetic and reconstructive medicine. , ... synthetic collagen for a decade, teasing out the details ...
Breaking Biology News(10 mins):NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3
... year in the Horn of Africa affected millions of people ... of several migratory songbird species, a study from University of ... the migration route was revealed by data collected from small ... an extended stay in the Horn of Africa. , The ...
... Entomologist Marshall Johnson , an extension specialist and ... the Distinguished Scientist of the Year Award from the ... (IOBC-NRS). Only one individual is recognized annually for ... career in the nearctic region , which encompasses ...
... DNA self-assembly techniques, researchers have developed a new ... the time required to create and test medications. ... Foundation (NSF) Small Business Innovation Research grant, researchers ... and began evaluating a drug for combating the ...
Cached Biology News:Drought in the Horn of Africa delays migrating birds 2UC Riverside entomologist named Distinguished Scientist of the Year 2Drag-and-drop DNA 2Drag-and-drop DNA 3Drag-and-drop DNA 4
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
... For use in hybridization incubators ... and GL 45 size PP plug-seal ... seal. Available in three lengths to ... plug-seal caps and O-rings available separately. ...
... extraction of DNA from agarose gels The SpinPrep ... of 150 bp to > 12,000 bp in size ... dissolve the gel slice, followed by adsorption of the ... format. After a wash step, the purified DNA is ...
Biology Products: